Clinical trial · no report yet · Phase 1/Phase 2
NCT06521567
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
- NCT06521567 ↗
- Active, not recruiting
- GlaxoSmithKline
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 2 | |
| Podcasts | 1 | |
| X threads | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Melanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrinsic Pontine Glioma (DIPG); Ependymoma; Osteosarcoma; Hepatic Tumors; Hepatoblastoma; Hepatocellular Carcinoma (HCC); Fibrolamellar Carcinoma; Rhabdomyosarcoma
- Interventions
- Cobolimab; Dostarlimab
- Arms
- Part 1- Dose determination · Experimental
- Part 2- Dose expansion · Experimental
- Enrollment
- 83 (estimated)
- Primary outcomes
- Part 1- Number of participants with Dose Limiting Toxicities (DLTs)
- Part 1- Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), immune-mediated adverse events (imAEs) and adverse events (AEs) leading to discontinuation occurring during the study
- Part 1- Serum concentration of Cobolimab
- Part 1- Serum concentration of Dostarlimab
- Part 1- Recommended Phase 2 Dose (RP2D) of Cobolimab and Dostarlimab combination
- Part 2- Confirmed Objective Response Rate (ORR)
- Part 2- Number of participants with TEAEs, SAEs, imAEs, TEAEs leading to death and AEs leading to discontinuation
- Part 2-Number of participants with changes in laboratory parameters, vital signs and cardiac parameters
- Sponsor
- GlaxoSmithKline
- Start
- Mar 6, 2025
- Primary completion
- Oct 13, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06521567 · updated Nov 12, 2025